Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Rheumatology

• Publication date

  2011-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.3899/jrheum.100665PMID 21239748
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of Indirect and Mixed Treatment Comparisons for Technology Assessment

  2012cited by this paper
• Biologics for rheumatoid arthritis: an overview of Cochrane reviews

  2009cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study

  2009cited by this paper
• Golimumab , a human antibody to tumour necrosis factor a given by monthly subcutaneous injections , in active rheumatoid arthritis despite methotrexate therapy : the GO-FORWARD Study

  2009cited by this paper
• Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

  2008cited by this paper
• Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

  2008cited by this paper
• Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

  2008cited by this paper
• Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons.

  2008cited by this paper
• Efficacy of Biologicals in the Treatment of Rheumatoid Arthritis

  2008cited by this paper
• Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

  2008cited by this paper
• Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.

  2008cited by this paper
• Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  2008cited by this paper
• A randomized, double‐blind, placebo‐controlled, phase III study of the human anti‐tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate

  2007cited by this paper
• Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

  2007cited by this paper
• Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti‐tumor necrosis factor &agr; agents

  2007cited by this paper
• The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review

  2007cited by this paper
• The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.

  2007cited by this paper
• Rheumatoid arthritis and spondyloarthropathies: geographical variations in prevalence in France.

  2007cited by this paper
• Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China

  2006cited by this paper
• Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

  2006cited by this paper
• The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial.

  2006cited by this paper
• Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison

  2006cited by this paper
• A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

  2006cited by this paper
• Prevalence of rheumatoid arthritis in France: 2001

  2005cited by this paper
• Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

  2004cited by this paper
• Combination of direct and indirect evidence in mixed treatment comparisons

  2004cited by this paper
• A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

  2004cited by this paper
• Overview of radiologic efficacy of new treatments.

  2004cited by this paper
• Overview of radiologic efficacy of new treatments.

  2004cited by this paper
• The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation.

  2003cited by this paper
• Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

  2003cited by this paper
• Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

  2003cited by this paper
• Guidelines for the management of rheumatoid arthritis: 2002 Update.

  2002cited by this paper
• Guidelines for the management of rheumatoid arthritis: 2002 update.

  2002cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

  1999cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Investigating underlying risk as a source of heterogeneity in meta-analysis.

  1997cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

  1995cited by this paper
• Rheumatoid arthritis.

  1990cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• Stochastic Relaxation, Gibbs Distributions, and the Bayesian Restoration of Images

  1984cited by this paper
• [Rheumatoid arthritis].

  1983cited by this paper
• Index

  1970cited by this paper
• Prevalence of Rheumatoid Arthritis

  1961cited by this paper
• Bmc Musculoskeletal Disorders Tumor Necrosis Factor Alpha Drugs in Rheumatoid Arthritis: Systematic Review and Metaanalysis of Efficacy and Safety

  year unknowncited by this paper

• The Role of TNF-α in Ischemic Stroke

  2026cites this paper
• How similar is similar enough? Assessment of indirect treatment comparisons to support similarity for NICE's cost comparison route.

  2025cites this paper
• Tumor-secreted TNF induces NCoA3 upregulation in breast cancer-associated adipocytes via TNFR1/NF-κB signaling.

  2025cites this paper
• Quantitation of certolizumab pegol by validated liquid chromatography methods

  2023cites this paper
• A critical review of the United States regulatory pathways for determining the equivalence of ef fi cacy between CT-P13 and original in fl iximab (Remicade ® )

  2020influential citation
• A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®)

  2020cites this paper
• A critical review of the United States regulatory pathways for determining the equivalence of ef fi cacy between CT-P13 and original in fl iximab (Remicade ® )

  2020cites this paper
• A review of network meta-analysis comparing biologics in the treatment of rheumatoid arthritis.

  2020cites this paper
• Anticytokine Therapy: The Newer Horizons Revisited

  2018cites this paper
• Applied Bayesian Methods in the Rheumatic Diseases.

  2018cites this paper
• Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece

  2017cites this paper
• Therapeutic Antibodies by Phage Display.

  2017cites this paper
• Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis

  2017cites this paper
• Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

  2017cites this paper
• Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison

  2016cites this paper
• Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.

  2016cites this paper
• Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.

  2016cites this paper
• Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?

  2016cites this paper
• Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials

  2016cites this paper
• Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France

  2016cites this paper
• ACP Journal Club: review: some TNF inhibitors increase adverse events in patients with rheumatoid arthritis.

  2015cites this paper
• Romatoid artritte sertolizumab pegol (CZP) kullan›m› Certolizumab pegol for the treatment of rheumatoid arthritis

  2015cites this paper
• Certolizumab for rheumatoid arthritis.

  2014cites this paper
• The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing

  2014cites this paper
• Effect of Combination Therapy on Joint Destruction in Rheumatoid Arthritis: A Network Meta-Analysis of Randomized Controlled Trials

  2014cites this paper
• Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis

  2014cites this paper
• Reporting of results from network meta-analyses: methodological systematic review

  2014cites this paper
• Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison

  2014cites this paper
• Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach

  2014cites this paper
• Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: a meta-analysis with indirect comparisons.

  2014cites this paper
• Network meta-analysis for comparing treatment effects of multiple interventions: an introduction

  2014cites this paper
• Therapeutic human monoclonal antibodies in inflammatory diseases.

  2014cites this paper
• The efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trials.

  2014cites this paper
• Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of rheumatoid arthritis

  2014cites this paper
• Jak porównać leki biologiczne stosowane w reumatologii? How compare biologics applied for rheumatic disorders?

  2014cites this paper
• How compare biologics applied for rheumatic disorders

  2014cites this paper
• Immune Compromise Associated with Biologics

  2014cites this paper
• Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

  2014cites this paper
• Targeting F Box Protein Fbxo3 To Control Cytokine-Driven Inflammation

  2013cites this paper
• A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis.

  2013cites this paper
• Incorporating data from various trial designs into a mixed treatment comparison model

  2013cites this paper
• This information is current as Cytokine-Driven Inflammation Targeting F Box Protein Fbxo 3 To Control

  2013cites this paper
• Current immunotherapy in rheumatoid arthritis.

  2013cites this paper
• Certolizumab Pegol

  2013cites this paper
• Efectos adversos neuropsiquiátricos de drogas inmunosupresoras utilizadas en Reumatología

  2013cites this paper
• Monoclonal antibodies in rheumatoid arthritis

  2013cites this paper
• Cytokine-Driven Inflammation Targeting F Box Protein Fbxo3 To Control

  2013cites this paper
• Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings

  2012cites this paper
• Regulation of interleukin 1α secretion by inflammasomes

  2012cites this paper
• Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis

  2012cites this paper
• Making More Valid Estimates of Treatment Effect using Observational Data in Uncommon Disease. The Warfarin in Scleroderma-associated Pulmonary Arterial Hypertension Model.

  2012cites this paper
• PMS88 Mixed Treatment Comparison, Cost-Effectiveness Analysis and Budget Impact Model in the Treatment of Rheumatoid Arthritis After Failure of Conventional Dmard Therapy Using Comprehensive Bayesian Decision Analytical Modelling

  2012cites this paper
• The IL-1 Receptor Antagonist Anakinra Enhances Survival and Function of Human Islets during Culture: Implications in Clinical Islet Transplantation

  2012cites this paper
• Update upon efficacy and safety of TNF-α inhibitors

  2012cites this paper
• Certolizumab pegol therapy of rheumatoid arthritis: Overview

  2011cites this paper
• Certolizumab pegol in the treatment of rheumatoid arthritis

  2011cites this paper
• Bayesian Inference: Statistical Gimmick or Added Value?

  2011cites this paper
• One target, different effects: a comparison of distinct therapeutic antibodies against the same targets

  2011cites this paper
• Anti-TNF treatment in rheumatoid arthritis.

  2011cites this paper
• A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis

  2011influential citation
• Application of Novel Quantitative Proteomic Technologies to Identify New Serological Biomarkers in Autoimmune Diseases

  2011cites this paper
• Clinical and epidemiological research

  2011cites this paper
• A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach

  2011cites this paper
• Open Access Rheumatology: Research and Reviews Dovepress Certolizumab in the Long-term Treatment of Rheumatoid Arthritis

  year unknowncites this paper